PRJNA764203
Targeted sequencing of a HNSCC patient tumor
Next generation sequencing of a HNSCC patient's recurrent tumor for 244 genes known to be somatically altered in HNSCC revealed a non-canonical PIK3CA mutation. The patient was enrolled in the TRIUMPH trial and assigned to receive alpelisib monotherapy based on detection of the PIK3CA mutation in his tumor.